clinical trial · NCT04240158
IW-6463 Safety Study in Healthy Elderly Subjects
OtherIW-6463Matching Placebo
brief summary
This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy male and female elderly participants.
started
Jan 6, 2020
primary completion
May 22, 2020
completion
May 22, 2020
last updated
Aug 16, 2024
detailed description
Participants will receive up to a total of 30 daily doses of study drug (15 days of daily IW-6463, only; 15 days of daily placebo, only) administered across two 15-day dosing periods (Period 1 and Period 2). The dosing periods will be separated by a 27-day washout. Participants will be randomized to a sequence of receiving IW-6463 for Period 1 and then placebo for Period 2, or vice versa.
official title
Evaluating the Safety, Tolerability, and Pharmacodynamic Properties of IW-6463 in Healthy Elderly Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol